Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
1. Introduction

The coronavirus disease 2019 (COVID-19) pandemic has resulted in widespread implementation of containment measures throughout the United States (US) and the majority of other countries. By mid-March 2020, many US states began enforcing travel restrictions, bans on large gatherings, closings of non-essential businesses, and/or stay-at-home orders in an attempt to curb transmission (Schuchat, 2020). There exists relatively little information about how COVID-19 and associated measures to curb infection have affected human behaviors. The behaviors that have gained attention are those related to access to care and overdose. It is plausible that the increase in personal "leisure" time due to widespread restrictions may be accompanied by an increase in demand for drugs and perhaps drug use itself. As such, we hypothesized that drug seizures, one potential proxy for drug availability, would also increase during the pandemic in a manner that may reflect increased rates of drug use, which would then warrant additional epidemiological research efforts.

Thus far, research examining drug use and related outcomes in relation to the COVID-19 pandemic has yielded mixed results. According to reports published by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), there was a decline in use of party drugs such as cocaine, ecstasy, and LSD in Europe during the first three months of the pandemic (EMCDDA, 2020a,b). The EMCDDA also reported that...
prevalence of marijuana use decreased among infrequent users and 
increased among frequent users. Smaller studies in the US also deter-
mined decreased prevalence of use of party drugs and higher frequency 
of marijuana use during early months of the COVID-19 pandemic (Bartel 
et al., 2020; Palamar et al., 2020; Starks et al., 2020). Along with re-
ported decreases in use of select drugs, international agencies also re-
ported decreased availability of drugs such as heroin, ecstasy, cocaine, 
and amphetamine during early months of the pandemic, both in Europe 
and in North America (EMCDDA, 2020a,b; United Nations Office on 
Drugs and Crime, 2020). Reduced availability was likely due to reduced 
production, difficulty trafficking shipments during restricted travel, and 
decreased demand for some drugs.

Despite data suggestive of decreases in drug use and availability 
during the early months of the pandemic, various studies have deter-
mained that overdoses and emergency medical services to transport 
overdose patients increased during this same period (Glober et al., 2020; 
Ochalek et al., 2020; Rodda et al., 2020; Slavova et al., 2020). In addi-
tion, studies investigating biospecimen testing in clinical laboratories 
found that there was a higher percentage of positive detection of 
cocaine, heroin, and fentanyl during the early months of the pandemic 
compared to before the pandemic (Niles et al., 2020; Wainwright et al., 
2020).

Given current conflicting information about changes in drug use, 
availability, and adverse drug-related outcomes after the onset of 
the COVID-19 pandemic, we examined trends in drug seizures in the US 
to provide additional insight to clarify how the pandemic and its associ-
ated restrictions have been affecting drug use. Although seizure data is not 
the most reliable indicator of prevalence of drug use, it can serve as an 
indicator of drug supply or availability and future use. For example, 
fewer seizures, or lower volumes of drugs seized, can reflect disruption 
of drug supply chains (EMCDDA, 2020b). Further, the number of fen-
tanyl seizures is strongly correlated with rates of synthetic 
opioid-involved deaths (Gladden et al., 2016; JAMA, 2017; Zibbell et al., 
2019); one study also found that cocaine seizures were positively asso-
ciated with cocaine-related emergency department visits (Wan et al., 
2016). Therefore, shifts in the number of seizures may not only indicate 
drug availability, but also indicate shifts in drug-related poisonings or 
deaths. In this analysis, we examined whether trends in drug seizures in 
the US shifted during the COVID-19 pandemic.

2. Methods

2.1. Procedure

Congress created The High Intensity Drug Trafficking Areas (HIDTA) 
program in 1988 to assist federal, state, local, and tribal law enforce-
ment agencies within areas determined to be critical drug trafficking 
regions in the US. To date, there are 33 HIDTAs, which oversee counties 
in 50 states, Puerto Rico, the US Virgin Islands, and the District of 
Columbia (High Intensity Drug Trafficking Area, 2019). HIDTAs 
encourage collaboration among law enforcement agencies with a goal to 
disrupt and dismantle drug trafficking organizations. HIDTAs collect 
data on drug seizures made by participating agencies. The HIDTA Per-
formance Management Process collects performance data submitted 
quarterly from all 33 HIDTAs. Five HIDTAs agreed to share drug seizure 
data with the National Drug Early Warning System (NDEWS) for the 
purpose of developing standard analytical methods that would eventu-
ally be used across the HIDTA program to examine seizure data. As such, 
we examined trends in seizures of marijuana, cocaine, methamphetamine, 
heroin, and fentanyl reported by five HID-
TAs—Washington/Baltimore, Chicago, Ohio, New Mexico, and North 
Florida.

2.2. Statistical analysis

We examined monthly trends in seizures between March 2019 and 
September 2020. March 2019 was chosen as the starting point as this 
was 12 months before COVID-19 was declared a worldwide pandemic 
by the World Health Organization. Joinpoint Regression version 4.8.0.1 
(National Cancer Institute, 2020) was used to examine trends. Also 
known as broken line, piecewise, multi-phase, or segmented regression, 
Joinpoint fits weighted least-square regression models to rates or counts 
on a log transformed scale (Ingram et al., 2018; Kim et al., 2000). It also 
uses Monte Carlo permutation tests with a Bonferroni correction for 
multiple testing and identifies models with the best-fit set of joinpoints. 
These are points (or ‘knots’) in trends that indicate significant shifting 
points. Poisson models were specified under the assumption of 
non-constant variance or heterogeneity over time. A separate joinpoint 
analysis was conducted for monthly counts of seizures regarding: 1) all 
drugs combined (limited to the five drugs in this study); and 2) for each 
drug separately: marijuana; cocaine; methamphetamine; heroin; and 
fentanyl. These analyses were then repeated examining trends in total 
weight of each drug seized per month. This secondary data analysis was 
exampt from review by the New York University Langone Medical 
Center institutional review board.

3. Results

We obtained data on 34,384 seizures between March 2019 and 
September 2020, 29,574 of which were identified as any of the five 
drugs we examined in this study, making up 86.0 % of all seizures. 
Within the five drugs examined, the plurality of seizures was marijuana 
(30.6 %, n = 9050), followed by cocaine (23.0 %, n = 6801), metham-
phetamine (21.9 %, n = 6491), heroin (17.3 %, n = 5104), and fentanyl 
(7.2 %, n = 2128). The total weight of marijuana seized was 56,704 kg, 
followed by cocaine (5152 kg), methamphetamine (2423 kg), heroin 
(1247 kg), and fentanyl (793 kg).

Trends in monthly seizure counts are presented in Fig. 1. With regard 
to all drug seizures combined, the number of seizures significantly 
decreased from March 2019 through April 2020 (β = −0.02, SE = 0.01, P 
= 0.046). While the increase after April 2020 only approached signifi-
cance (β = 0.11, SE = 0.07, P = 0.103), the number of overall seizures in 
August of 2020 (n = 2088) exceeded the highest pre–COVID-19 count in 
our analysis (1777 in June 2019). With respect to marijuana, the num-
ber of seizures significantly decreased from March 2019 through April 
2020 (β = −0.03, SE = 0.01, P = 0.005), and then significantly increased 
through September 2020 (β = 0.10, SE = 0.04, P = 0.028). The number 
seized in August 2020 (n = 665) exceed the highest pre-COVID-19 
count in our analysis (614 in March 2019). Multiple slopes were not 
detected for cocaine seizures and the overall single slope was not sig-
nificant. With regard to methamphetamine, the number of seizures 
steadily decreased from March 2019 through April 2020 (β = −0.02, SE 
= 0.01, P = 0.026), and then significantly increased through September 
2020 (β = 0.11, SE = 0.04, P = 0.010). The number seized in August 
2020 (n = 476) exceeded the highest pre-COVID-19 count in our analysis 
(385 in June 2019). No significant slopes were detected regarding heroin 
seizures, but the number of fentanyl seizures significantly increased 
to across time (β = 0.05, SE = 0.01, P < .001). The increase in fentanyl 
seizures did not significantly shift during the pandemic. Supplemental 
Fig. 1 presents trends stratified by area.

Trends in total weight of seizures are presented in Fig. 2. With 
respect to the total weight of all five drugs combined, the weight 
remained stable from March 2019 through April 2020 and then sig-
ificantly increased through September 2020 (β = 0.32, SE = 0.10, P 
= .007). The weight in August 2020 (11,698 kg) exceeded the highest pre-
COVID-19 monthly weight in our analysis (5040 kg in December 2019). 
With respect to marijuana, three non-significant pre-COVID-19 slopes 
were identified, and we detected a steep significant increase from April 
2020 through September (β = 0.40, SE = 0.08, P = .001). The total 
weight in August 2020 (11,194 kg) greatly exceeded the highest pre-
COVID-19 weight for marijuana seizures in our analysis (4744 kg in 
December 2019). Increases in weight were not detected for the total
weight of seizures involving methamphetamine or fentanyl, and the overall single slopes were not significant. There was a pre-COVID-19 increase in weight of cocaine seizures which peaked in June 2019 ($\beta = 0.98$, SE $= 0.38$, $P = .027$) and thereafter decreased in a non-significant manner. The total weight of heroin seizures significantly decreased across time ($\beta = -0.08$, SE $= 0.02$, $P = .003$), but multiple slopes were not detected. Supplemental Fig. 2 presents trends stratified by area.

4. Discussion

To our knowledge, this is the first study to examine potential shifts in drug seizures during the COVID-19 pandemic. We detected a significant decrease in overall drug seizures near the beginning of the pandemic with a nadir in April 2020, and then an increase through September. These shifts were driven by marijuana and methamphetamine seizures. In addition, the volume of seizures also significantly increased after April 2020, and this increase was clearly driven by an increase in volume of marijuana seizures. Peaks in number and volume of seizures for marijuana in particular surpassed pre-COVID-19 peaks.

Most published studies that have examined drug trends in relation to COVID-19 focused on the early months of the pandemic, but this study examined trends through roughly six months after the start. We did not detect significant dips in seizures involving cocaine or heroin during the pandemic, so our findings do not appear to corroborate those from other studies suggesting decreased use or availability. However, other studies did report a higher number of people using fentanyl after the onset of COVID-19 (Niles et al., 2020; Wainwright et al., 2020), possibly as a replacement for heroin, which reportedly decreased in availability. Indeed, we detected an upward shift in seizures of fentanyl beginning even before the pandemic. Although some other studies found that the frequency of marijuana use increased shortly into the pandemic among certain populations (Bartel et al., 2020; EMCDDA, 2020a, b; Palamar et al., 2020; Starks et al., 2020), we detected an initial decrease in seizures followed by a steep increase in later months. It is unknown if increased frequency of prevalence of marijuana use was associated with lagged increases in seizures.

Ultimately, the overall increase in drug seizures as the COVID-19 pandemic progressed warrants additional research investigating how prevalence of drug use has changed during this period, as well as to determine potential changes in drug availability, poisonings, and deaths. While decreases in seizures, for example, likely indicate decreases in drug availability, it is also possible that decreases may indicate reduced law enforcement during the early months of the pandemic. Further, it is unknown whether the high post-COVID-19 peaks indeed represent greater availability of marijuana and methamphetamine or whether law enforcement officials were merely ‘catching up’ regarding previous months of delayed seizures.

Fig. 1. Trends in drug seizure counts from March 2019 through September 2020. Raw (observed) counts and fitted trend estimates are presented for seizures involving 1) any of the five drugs, 2) marijuana, 3) cocaine, 4) methamphetamine, 5) heroin, and 6) fentanyl. Y axes are presented on different scales across drugs depending on the number of seizures.
4.1. Limitations

We were only able to obtain data from five HIDTAs, so it is possible that seizures from these areas in the US do not fully reflect seizures in other areas. Analyses were limited to data from one year prior to the start of the COVID-19 pandemic; therefore, trends detected during COVID-19 are relative only to this period before the start of the pandemic. Drug samples testing positive for any fentanyl were coded as fentanyl seizures in the HIDTA database, which could lead to overestimates in total volume. Carfentanil seizures were also coded as fentanyl seizures in this analysis although these only consisted of 2.4% of fentanyl-related seizures. When examining trends in weight of total seizures, we only included drugs seized that were measured in kg. For example, 2.7% of marijuana seizures were recorded in "dosage units" (which most commonly refers to pills) or in liters. We could not convert dosage units or liters to kg with confidence, so we omitted these seizures when examining volume. Finally, we did not have access to arrest data or data on the number of police officers (or number of hours worked), so we could not determine whether decreases in seizures were a function of restricted police activity during the pandemic due to health concerns.

4.2. Conclusion

We detected significant decreases in marijuana and methamphetamine seizures right at the beginning of the COVID-19 pandemic and then detected increases in the following months exceeding pre-COVID-19 seizure rates. We did not, however, detect significant shifts during COVID-19 with regard to seizures involving cocaine, heroin, or fentanyl, although the number of fentanyl seizures increased in a stable manner, independent of COVID-19. While more research is needed, these data indicate that while availability of various drugs decreased during the beginning of the pandemic, seizures of marijuana and methamphetamine in particular then surpassed pre-COVID-19 levels roughly six months into the pandemic. Future studies should consider harmonizing seizure data along with data from surveys, poisonings, and deaths, in order to determine the most accurate picture of drug use trends during the pandemic.

Contributors

All authors are responsible for this reported research. J. Palamar conceptualized and designed the study, and J. Palamar conducted the statistical analyses. T. Carr provided access to the data. A. Le assisted with graphical representation of the findings. All authors drafted the manuscript, and all authors interpreted results, and critically reviewed and revised the manuscript. All authors approved the final manuscript as submitted.
Role of funding source

Research reported in this publication was supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Numbers U01DA051126 (Cottler) and R01DA044207 (Palamar). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Declaration of Competing Interest

The authors report no declarations of interest.

Acknowledgments

J. Palamar and L. Cottler are funded by the National Institutes of Health (NIH) (R01DA044207, PI: Palamar, and U01DA051126, PI: Cottler).

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:https://doi.org/10.1016/j.drugalcdep.2021.108580.

References

Bartel, S.J., Sherry, S.B., Stewart, S.H., 2020. Self-isolation: a significant contributor to cannabis use during the COVID-19 pandemic. Subst. Abus. 41 (4), 409–412.

European Monitoring Centre for Drugs and Drug Addiction, 2020a. EMCDDA Trendspotter Briefing: Impact of COVID-19 on Patterns of Drug Use and Drug-related Harms in Europe. Lisbon. Retrieved from: https://www.emcdda.europa.eu/publications/ad-hoc-publication/impact-covid-19-patterns-drug-use-and-harms_en.

European Monitoring Centre for Drugs and Drug Addiction, 2020b. Impact of COVID-19 on Drug Markets, Drug Use, Drug-related Harms and Responses in East European Neighbourhood Policy Countries. Retrieved from: https://www.emcdda.europa.eu/publications/ad-hoc-publication/impact-covid-19-east-enp-countries_en.

Gladden, R.M., Martinez, P., Seth, P., 2016. Fentanyl law enforcement submissions and increases in synthetic opioid-involved overdose deaths - 27 states, 2013-2014. MMWR Morb. Mortal. Wkly. Rep. 65 (33), 837–843.

Glober, N., Mohler, G., Huynh, P., Arkim, T., O’Donnell, D., Carter, J., Ray, B., 2020. Impact of COVID-19 pandemic on drug overdoses in Indianapolis. J. Urban Health 97 (6), 802–807.

High Intensity Drug Trafficking Area, 2019. Annual Report 2019. Retrieved from: http://www.hidta.org/wp-content/uploads/2020/04/AnnualReport_2020_final.pdf.

Ingram, D.D., Malec, D.J., Makuc, D.M., Kruszon-Moran, D., Gindi, R.M., Albert, M., Beresovsky, V., Hamilton, B.E., Holmes, J., Schiller, J., Sengupta, M., 2018. National Center for Health Statistics guidelines for analysis of trends. Vital Health Stat. 2 (179), 1–71.

JAMA, 2017. As heroin death rates rose, so did illicit drug seizures. JAMA 318 (14), 1315.

Kim, H.J., Fay, M.P., Feuer, E.J., Midthune, D.N., 2000. Permutation tests for joinpoint regression with applications to cancer rates. Stat. Med. 19 (3), 335–351.

National Cancer Institute, 2020. Joinpoint Regression Program, Version 4.8.0.1. Statistical Methodology and Applications Branch. Surveillance Research Program.

Niles, J.K., Gudin, J., Radcliff, J., Kaufman, H.W., 2020. The Opioid Epidemic Within the COVID-19 Pandemic: Drug Testing in 2020. Popul Health Manag. Epub ahead of print.

Ochalek, T.A., Cumpton, K.L., Wills, B.K., Gal, T.S., Moeller, F.G., 2020. Nonfatal opioid overdoses at an urban emergency department during the COVID-19 pandemic. JAMA 324 (16), 1673–1674.

Palamar, J.J., Le, A., Acosta, P., 2020. Shifts in Drug Use Behavior Among Electronic Dance Music Partygoers in New York During COVID-19 Social Distancing. Subst. Use Misuse, pp. 1–7.

Rodd, L.N., West, K.L., LeSaint, K.T., 2020. Opioid overdose-related emergency department visits and accidental deaths during the COVID-19 pandemic. J. Urban Health 97 (6), 808–813.

Schuchat, A., 2020. Public health response to the initiation and spread of pandemic COVID-19 in the United States, February 24–April 21, 2020. MMWR Morb. Mortal. Wkly. Rep. 69 (18), 551–556.

Slavova, S., Rock, P., Bush, H.M., Quisenberry, D., Walsh, S.L., 2020. Signal of increased opioid overdose during COVID-19 from emergency medical services data. Drug Alcohol Depend. 214, 108176.

Starks, T.J., Jones, S.S., Sauerilmich, D., Benedict, M., Adebayo, T., Cain, D., Simpson, K. N., 2020. Evaluating the impact of COVID-19: a cohort comparison study of drug use and risky sexual behavior among sexual minority men in the U.S.A. Drug Alcohol Depend. 216, 108260.

United Nations Office on Drugs and Crime, 2020. COVID-19 And the Drug Supply Chain: From Production and Trafficking to Use. Vienna, Austria. Available at: http://www.unodc.org/documents/data-and-analysis/covid/Covid-19-and-drug-supply-chain-Mai2020.pdf.

Wainwright, J.J., Mikre, M., Whitley, P., Dawson, E., Huskey, A., Lukowiak, A., Giroir, B. P., 2020. Analysis of drug test results before and after the us declaration of a national emergency concerning the COVID-19 outbreak. JAMA 324 (16), 1674–1677.

Wan, W.Y., Weatherburn, D., Wardlaw, G., Sareifud, V., Sara, G., 2016. Do drug seizures predict drug-related emergency department presentations or arrests for drug use and possession? Int. J. Drug Policy 27, 74–81.

Zibbell, J.E., Aldridge, A.P., Caughon, D., DeFiore-Hymer, J., Conway, K.P., 2019. Association of law enforcement seizures of heroin, fentanyl, and carfentanil with opioid overdose deaths in Ohio, 2014-2017. JAMA Netw Open 2 (11), e191466.